Search

Your search keyword '"Perren, T"' showing total 318 results

Search Constraints

Start Over You searched for: Author "Perren, T" Remove constraint Author: "Perren, T"
318 results on '"Perren, T"'

Search Results

1. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

9. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

12. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor

25. Abstract P4-13-14: “Real world” characteristics, treatment patterns and outcomes of patients with hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC)

26. Clinical utility of complex multi-platform profiling in metastatic cancer patients

27. PCN219 - CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC HORMONE RECEPTOR POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE (HER2-) BREAST CANCER IN CLINICAL PRACTICE: RETROSPECTIVE ANALYSIS FROM LEEDS CANCER CENTRE

28. The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy

30. ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis

34. ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer

35. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study

36. Abstract OT1-03-13: A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC)(NCT02423603)

37. 929O_PR - ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis

39. Chemotherapy for ovarian cancer--a consensus statement on standard practice

41. A phase 3 trial of bevacizumab in ovarian cancer

47. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial

Catalog

Books, media, physical & digital resources